Key result
Early vasopressin shows no association with major adverse kidney events after cardiac surgery.
Why the study?
It was unclear whether early vasopressin use is associated with major adverse kidney events in patients requiring vasopressor support after cardiac surgery.
Does vasopressin use within 24 hours of ICU admission reduce major adverse kidney events at 30 days in adults requiring vasopressor support after cardiac surgery?
Cohort (n=3,753)
Yes
Does vasopressin use within 24 hours of ICU admission reduce major adverse kidney events at 30 days in adults requiring vasopressor support after cardiac surgery?
Odds Ratio: 1.02 (95% CI 0.76–1.38)
p-value: p=0.88
Early adjunctive vasopressin use in patients requiring vasopressor support after cardiac surgery is not associated with a reduction in major adverse kidney events or mortality at 30 days.
Does not support early vasopressin to reduce kidney events after cardiac surgery; leaves open possible severity-specific benefit for prospective trials.
No takes yet. Share an insight, caveat, or question.
White et al. (2026) conducted a cohort in Requiring vasopressor support after cardiac surgery (n=3,753). Vasopressin vs. No vasopressin was evaluated on Major adverse kidney events at 30 days (composite of death, new renal replacement therapy, or creatinine doubling) (OR 1.02, 95% CI 0.76-1.38, p=0.88). Early vasopressin use was not associated with major adverse kidney events at 30 days in adults requiring vasopressors after cardiac surgery (OR 1.02; 95% CI 0.76-1.38; p=0.88).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: